1. Academic Validation
  2. Brain Metastasis from EGFR-Mutated Non-Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up-Regulates PDL1 and Promotes Immune Escape

Brain Metastasis from EGFR-Mutated Non-Small Cell Lung Cancer: Secretion of IL11 from Astrocytes Up-Regulates PDL1 and Promotes Immune Escape

  • Adv Sci (Weinh). 2024 May 2:e2306348. doi: 10.1002/advs.202306348.
Mengyi Tang 1 Mingxin Xu 1 Jian Wang 1 Ye Liu 2 Kun Liang 1 Yinuo Jin 1 Wenzhe Duan 1 Shengkai Xia 1 Guohui Li 2 Huiying Chu 2 Wenwen Liu 1 3 Qi Wang 1
Affiliations

Affiliations

  • 1 the Second Affiliated Hospital of Dalian Medical University, 467 Zhongshan Road, Dalian, 116027, China.
  • 2 Laboratory of Molecular Modeling and Design, State Key Laboratory of Molecular Reaction Dynamics, Dalian Institute of Chemical Physics, Chinese Academy of Science, 457 Zhongshan Road, Dalian, 116023, China.
  • 3 Cancer Translational Medicine Research Center, The Second Hospital, Dalian, Medical University, 467 Zhongshan Road, Dalian, 116027, China.
Abstract

Patients who have non-small cell lung Cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations are more prone to brain metastasis (BM) and poor prognosis. Previous studies showed that the tumor microenvironment of BM in these patients is immunosuppressed, as indicated by reduced T-cell abundance and activity, although the mechanism of this immunosuppression requires further study. This study shows that reactive astrocytes play a critical role in promoting the immune escape of BM from EGFR-mutated NSCLC by increasing the Apoptosis of CD8+ T lymphocytes. The increased secretion of interleukin 11(IL11) by astrocytes promotes the expression of PDL1 in BM, and this is responsible for the increased Apoptosis of T lymphocytes. IL11 functions as a ligand of EGFR, and this binding activates EGFR and downstream signaling to increase the expression of PDL1, culminating in the immune escape of tumor cells. IL11 also promotes immune escape by binding to its intrinsic receptor (IL11Rα/glycoprotein 130 [gp130]). Additional in vivo studies show that the targeted inhibition of gp130 and EGFR suppresses the growth of BM and prolongs the survival time of mice. These results suggest a novel therapeutic strategy for treatment of NSCLC patients with EGFR mutations.

Keywords

astrocytes; brain metastasis; epidermal growth factor receptor; immune escape; interleukin‐11.

Figures
Products
Inhibitors & Agonists
Other Products